12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Sarilumab: Completed Phase II/III enrollment

The partners disclosed in their 3Q12 earnings that they completed enrollment of 1,197 patients with moderate to severe active RA who had an inadequate response to methotrexate in the double-blind, international Phase II/III SARIL-RA-MOBILITY trial evaluating 150...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >